Aspire Biopharma
ASBP
17 hedge funds and large institutions have $18.1M invested in Aspire Biopharma in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 5 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
1% more capital invested
Capital invested by funds: $17.9M → $18.1M (+$235K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
11% less funds holding
Funds holding: 19 → 17 (-2)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$1.29M |
| 2 |
FPA
First Pacific Advisors
El Segundo,
California
|
+$618K |
| 3 |
CS
Clear Street
New York
|
+$552K |
| 4 |
QL
Quarry LP
New York
|
+$381K |
| 5 |
FTCM
Fir Tree Capital Management
New York
|
+$342K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PSAMP
P. Schoenfeld Asset Management (PSAM)
New York
|
-$1.45M |
| 2 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
-$1.11M |
| 3 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$689K |
| 4 |
RCM
Robinson Capital Management
Grosse Pointe Farms,
Michigan
|
-$13.2K |
| 5 |
TI
Tidal Investments
Milwaukee,
Wisconsin
|
-$13.2K |
ASBP Hedge Fund Activity: Q1 2024 in Review
17 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma (ASBP) for Q1 2024, worth a combined $18.1M — up 1.3% from $17.9M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ASBP and 4 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 3 added.
The largest buyer was Cowen and Company, opening a new position worth an estimated $1.29M. The largest seller was P. Schoenfeld Asset Management (PSAM), exiting entirely with an estimated $1.45M sold.
- 17 institutional investors held Aspire Biopharma (ASBP) as of Q1 2024, down from 19 in Q4 2023.
- Funds reported $18.1M of Aspire Biopharma stock for Q1 2024, up 1.3% quarter-over-quarter.
- 4 funds opened new Aspire Biopharma positions in Q1 2024 and 5 closed out, a net change of -1 holder.
- The largest Aspire Biopharma buyer in Q1 2024 was Cowen and Company, an estimated $1.29M added.
- The largest Aspire Biopharma seller in Q1 2024 was P. Schoenfeld Asset Management (PSAM), an estimated $1.45M sold.
Based on aggregated 13F filings for Q1 2024.